Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 10/20 | 0.40 |
| ▸ | MERTK | Q12866 | 10/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 10/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31396521 | 0.98 | PTPN11 (0.50) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL31396608 | 0.95 | PTPN11 (0.46) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL31396485 | 0.94 | PTPN11 (0.48) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL31396613 | 0.94 | PTPN11 (0.48) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL31396510 | 0.94 | PTPN11 (0.47) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL31396582 | 0.94 | PTPN11 (0.48) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL30280428 | 0.92 | PTPN11 (0.46) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL31396568 | 0.92 | PTPN11 (0.46) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL31396513 | 0.92 | PTPN11 (0.47) | PTPN11CHEK1ACHEAXLMERTK | |
| SCHEMBL31396540 | 0.92 | PTPN11 (0.45) | PTPN11CHEK1ACHEAXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2023064218-A1 | TYRO3 INHIBITORS | Halia Therapeutics, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | TYRO3, TYR, TH | PTPN11 80/4885CHEK1 3068/4885ACHE 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.